Celltrion’s Remsima SC Will No Longer Need IV Loading
EMA Committee Endorses Direct Subcutaneous Use Of Infliximab Biosimilar
Celltrion has received an endorsement from the European Medicines Agency that means that its Remsima SC subcutaneous formulation of infliximab can be used directly in rheumatoid arthritis patients, without the need for intravenous loading first.
